

# Leading the way in ophthalmic innovation

Rayner manufactured the world's first IOL in 1949, and has remained at the forefront of innovation for over 70 years, focused on providing you and your patients with the best IOLs and ophthalmic solutions - always driven by science to improve patient outcomes and safety.

Rayner is the only manufacturer of IOLs in the UK, with its state-of-the-art manufacturing plant and Global Headquarters on the South Coast of England.

1910 1949 1979 Rayner is founded in London, UK.

Rayner makes the world's first IOL.

Rayner has the first IOL approved by the US FDA.

2007

Rayner launches:

- The first multifocal toric IOL
- The first pseudophakic supplementary IOL
- The first FDA approved IOL from a non-American manufacturer in two decades.

2016

- Brand new HQ and state-of-the-art manufacturing facility opens in Worthing, UK.
- RayOne fully preloaded IOL system is unveiled.
- Rayner acquires Moorfields Pharmaceuticals.

2017

RayOne Trifocal premium preloaded IOL is launched.

2018

- RayOne Hydrophobic and RayOne Toric preloaded IOLs are released.
- Sulcoflex Trifocal, the world's first supplementary trifocal IOL is launched.
- AEON eye drop family is introduced, designed specifically for before and after surgery.

2019

- RayPRO digital platform for patient reported outcomes data is released.
- RayOne Trifocal Toric is launched, completing Rayner's trifocal IOL family.

2020

RayOne EMV enhanced monofocal IOL is launched.

2021

2022

RayOne Hydrophobic BLF is released, Rayner's first blue light filtering IOL.

RayOne EMV Toric astigmatism-correcting enhanced monofocal IOL is launched.






# Trifocal IOL solutions for all your patients

Patient expectations from lens surgery are changing, with an increasing desire to be spectacle free as they continue to lead highly active and social lifestyles until much later in life.

Whether your patients are having cataract surgery or visiting you for refractive enhancement, our complete family of trifocal IOLs are clinically proven to provide them with the best visual outcomes.

- RayOne Trifocal preloaded IOL for placement in the capsular bag
- RayOne Trifocal Toric preloaded IOL for placement in the capsular bag and correction of preoperative corneal astigmatism
- Sulcoflex Trifocal supplementary IOL for placement in the ciliary sulcus, with optional correction of refractive change or error



### Optimised diffractive design

Our family of trifocal IOLs use Rayner's patented diffractive profile that was designed in partnership with a leading European technology institute.

This new design of diffractive technology is the most advanced optic in our history and possibly the most advanced in the industry.

The diffractive surface is a construct of two profiles to form our patented design:



Graphical representations only of diffractive surface pattern.

Rayner's diffractive trifocal design has fewer rings on the optic surface than many trifocal IOLs for reduced potential visual disturbances and improved night vision.

# 4.5 mm diffractive >4.5 mm trifocal zone distance zone

#### **FEATURES**


- 16 diffractive rings/steps
- 4.5 mm diffractive zone
- >4.5 mm monofocal, distance

#### **PATIENT BENEFITS**


- Reduces visual disturbances
- Developed to be less dependenton pupil size or lighting conditions
- Improves distance vision in mesopic condition

### Our patented diffractive step trifocal technology reduces light loss to only 11%

- 89% of light is transmitted to the retina with a pupil of 3.0 mm
- · Half the light is allocated for distance
- Remaining light is divided between near and intermediate vision








#### Comfortable transition from near to distance activities


Our trifocal optic improves intermediate visual acuity, enabling patients to feel more comfortable transitioning from near to distance activities



# Clinically-proven and industry leading trifocal technology

#### Comparable outcomes

In a retrospective study of RayOne Trifocal and Sulcoflex Trifocal in 40 eyes, the defocus curve shows comparable visual acuity results and reports similar outcomes.




## EXCELLENT REFRACTIVE PREDICTABILITY

At three months.


100%

of eyes within ±0.5D of the target SEQ<sup>2</sup>




#### Less photic phenomena

In a prospective study of 60 eyes, a statistically significant difference favouring the RayOne Trifocal versus the FineVision POD F was achieved in an objective evaluation of photic phenomenon.<sup>2</sup>



#### Less photic phenomena and increased patient satisfaction

In a prospective comparative study of 64 eyes of 32 patients, the RayOne Trifocal group is associated with better scores for glare, symptoms and near and distance VA against the PanOptix Trifocal group.<sup>15</sup>



In a prospective comparative study of 60 eyes<sup>2</sup>

40% VS. 67% Glare


40% VS. 53%

7% VS. 33% Difficulties in depth perception

RayOne Trifocal FineVision POD F

#### 100% spectacle independence

In a prospective study of 16 eyes implanted with RayOne Trifocal, 100% of patients achieved spectacle independence and agreed they would have the operation again at 1 month follow up.  $^3$ 



For me, the most important question for judging patient satisfaction asks...

'Would you repeat the treatment with the same procedure?'

and 100% said



– Fernando Llovet-Osuna, MD, PhD, Medical Director of Clínica Baviera, Spain¹





- Industry leading 11% light loss<sup>2</sup>
- Diffractive +3.5 D near add, +1.75 D intermediate add
- Fully preloaded from 0.0 D to +30.0 D (0.5 D increments)



- Aberration-neutral aspheric optic for visual quality and acuity in all light conditions
- Amon-Apple enhanced square edge for minimal PCO 1.7% at 24 months<sup>4</sup>
- Based on proven haptic technology for excellent stability<sup>5</sup>
- Zero glistenings
- Biocompatible
   hydrophilic acrylic
   material with a long
   safety record over
   9 million lenses sold
   since 2003
- Fully preloaded across the entire power range

### Proven haptic technology for excellent stability

Any rotation, tilt or decentration of a multifocal lens could affect patient outcomes and cause phototopic disturbances. Our anti-vaulting haptic technology gives proven rotational and centrational stability, plus excellent fixation in the capsular bag:

- Superb centration Average offset of only 0.08 mm 3 to 6 months after surgery<sup>5</sup>
- Excellent rotational and torsional stability 1.83° mean IOL rotation
   3 to 6 months after surgery<sup>5</sup>



Outer haptics begin to take up the compression forces of post-operative capsule contraction



Outer haptics engage the inner haptics

STAGE 2





Haptic tips gently mee
IOL optic and are effe






#### **STATS**

- 1.83° mean post-operative rotation at 3 to 6 months<sup>5</sup>
- 100% lenses rotated ≤5°5
- 0.08 mm average centration offset at 3 to 6 months<sup>5</sup>

#### **FEATURES & BENEFITS**

- Correct more of your patients, even those with significant corneal astigmatism.
- Proven rotational stability and centration<sup>5</sup> with predictable, sustainable and accurate visual results
- Aberration-neutral aspheric optic for visual quality and acuity in all light conditions
- Fully preloaded across the entire power range
- Simplified range of IOL plane cylinders:
  - +0.75 D
  - +1.5 D
  - +2.25 D
  - +3.0 D
  - +3.75 D
  - +4.5 D

### Prevalence of corneal astigmatism prior to cataract surgery



### RayOne injector








- Easy to use<sup>6</sup>
- i. Minimal learning curve
- ii. Minimises error
- Efficient IOL delivery time<sup>6</sup>
- i. Designed for repeatability
- ii. Reduces operating time
- Step 1: Insert OVD into cartridge via port
- Step 2: Lock cartridge ready for implantation

#### **FEATURES & BENEFITS**

- 1.65 mm nozzle for2.2 mm incision
- Smallest fully preloaded injector nozzle
- i. Ease of insertion
- ii. Enables true micro incision
- Ergonomic design for ease of handling
- Single handed plunger with minimal force required
- Parallel sided for minimal stretch
- i. 2.2 mm delivery
- ii. Maintains incision architecture



### Unique patented Lock & Roll technology for consistent delivery

- Rolls the lens to under half its size before injection
- i. Consistent, smoother delivery
- ii. Reduces insertion forces
- Fully enclosed cartridge with no lens handling
- i Reduces the risk of lens damage
- ii. Minimises chance of contamination

#### Lock & Roll technology








Consistently locked and rolled to under half its size in one simple action



#### INDICATIONS8,12


- Presbyopia (DUET procedure)
- Pseudophakic presbyopia\* (secondary enhancement)
- Post-surgical ametropia
- Patients who have experienced a change in their post-op refraction



#### **FEATURES & BENEFITS**

- Large 14.0 mm overall length with undulating haptics, designed for stable fixation in the ciliary sulcus
- Unique undulating round edge haptic design with 10° angulation
- Excellent centration stability compared to capsular bag fixated multifocal IOLs7
- Smooth undulating haptics to minimise the risk of adverse tissue reaction in the sulcus
- \*Contraindicated for implantation into eyes with multifocal capsular bag IOLs.

#### Designed to avoid the potential problems of conventional "piggy-back" IOLs<sup>8,9,10</sup>







Sulcoflex Trifocal DUET procedure

#### What is a DUET procedure?

The Sulcoflex Trifocal DUET procedure involves the sequential implantation of a primary capsular bag IOL and a supplementary Sulcoflex Trifocal sulcus IOL. This is done as a planned DUET procedure during the initial cataract surgery.

The DUET is an easy procedure, adding little time to the overall cataract surgery, yet offers an elegant and adjustable solution.

#### How do I perform a DUET procedure?

During the DUET procedure the capsular bag IOL is implanted first and treats the sphere - and where required cylinder - correction power for distance vision.

Then a plano Sulcoflex Trifocal is implanted which features our patented trifocal optics with a +3.50 D add for near vision and +1.75 D add for intermediate vision.

Combining the two lenses provides the patient with an opportunity for a spectacle free solution.

### Injector

Implantation of the Sulcoflex Trifocal is made easy with the Medicel ACCUJECT 1.80-1 (LP604540) - recommended and provided by Rayner.

#### MEDICEL ACCUJECT

Single handed injector with soft tip plunger. ACCUJECT's 1.8 mm nozzle tip allows for a sub 2.2 mm incision.

### A wider patient selection with the Sulcoflex Trifocal DUET procedure

There are several reasons why a patient may not be suitable for a capsular bag multifocal IOL. Through the option of reversibility, the Sulcoflex Trifocal DUET procedure may offer a solution for these patients.

Works with any monofocal or toric primary capsular bag IOL.

### Exploiting the benefits of reversibility and adjustability

Unlike capsular bag multifocal IOLs or refractive laser treatments, the Sulcoflex Trifocal DUET procedure is easily reversed. Refractive change or surprise cannot be predicted, and nor can a failure to neuroadapt. Through the DUET procedure, the optic system can be easily adjusted with a different Sulcoflex Trifocal or converted back to monofocality in a straightforward procedure.

- Plan for excellence with a simultaneous implantation
- Treat ametropia after cataract surgery
- Reversible more flexibility for you and your patient

It may seem counter-intuitive to implant a lens in anticipation of its removal, but for premium channel cataract and refractive surgeons, the ability to offer patients the benefits of a specialist lens knowing that the procedure can be reversed at a later date, is highly reassuring.


The Sulcoflex Trifocal DUET procedure empowers surgeons with the ability to offer refractive treatments to their patients without needing to invest in expensive laser equipment. This cost-efficient treatment option can easily be incorporated into any existing cataract surgery environment.

### A new opportunity for pseudophakic patients

There are estimated to be 100 million pseudophakic patients globally, with approximately 92% having had a monofocal IOL implanted (Market Scope 2018). Although monofocal IOLs improve distance vision, patients are typically left spectacle dependent for tasks involving near and intermediate vision. With personal technology playing an important role in today's world and cataract patients remaining highly active until later in life, many are demanding the opportunity to become spectacle free.

Cataract patients may have been unaware of the trifocal IOL options available to them at the time of their original surgery. Sulcoflex Trifocal can be implanted any time after cataract surgery, irrespective of the monofocal or toric IOL in the capsular bag, giving pseudophakic patients the opportunity to perform near and intermediate distance tasks without the need for spectacles. Due to its reversibility, Sulcoflex Trifocal also allows patients that were previously deemed potentially unsuitable for trifocal IOLs to be re-evaluated.

Sulcoflex Trifocal creates new surgery opportunities for cataract and refractive surgeons, allowing them to offer a large population of pseudophakic patients the chance to become spectacle free with an adjustable and reversible solution.



# When considering a solution for presbyopia, what is important to you?

### With the Rayner Sulcoflex platform, you can expect the following:

- Exceptional light usage
- Ease of use11
- Efficacy and patient outcomes<sup>11</sup>
- Versatility to treat a wider range of patients12
- An adjustable solution for peace of mind
- Increased accuracy with quarter dioptre steps

#### Predictability7,8,12

- Proven to provide better centration compared to capsular bag multifocal IOLs
- Predictable refractive outcomes; high visual acuity

#### High patient satisfaction<sup>12</sup>

- · Low complication rate
- · Stable long-term refractive results

### Reduced surgical risk associated with IOL exchange<sup>8,9,13</sup>

- Less surgical trauma than primary IOL exchange
- Avoids sometimes difficult removal of fibrosed, fixated primary implant
- Allows for implantation reversibility



"The world's first trifocal supplementary IOL may be used in routine cataract procedures (DUET) or in pseudophakes for presbyopic correction. This IOL concept allows the surgeon to adjust the optical system to any unpredictable situation in the future."

Professor Michael Amon MD, Head of the Department of Ophthalmology at the Academic Teaching Hospital of St John, Vienna, Austria

### Support the best visual outcomes with...

#### **AEON**

An eye drop family designed specifically to support visual outcomes and patient satisfaction before and after surgery.

Learn more at rayner.com/aeon



### Ray**PRo**<sup>+</sup>

A free mobile and web-based digital platform that collects insightful Patient Reported Outcomes (PROs) over three years.

Learn more at rayner.com/raypro



### **Technical information**

Model Name	RayOne Trifocal RAO603F	RayOne Trifocal Toric RAO613Z	Sulcoflex Trifocal IOL703F			
Power Range	Trifocal: 0.0 D to +30.0 D (0.5 D increments)  Trifocal Toric: Spherical Equivalent: +6.0 D to +30.0 D (0.5 D increments)  Cylinders: +0.75 D, +1.5 D, +2.25 D, +3.0 D, +3.75 D, +4.5 D  Trifocal, diffractive, +3.5 D near add and +1.75 D intermediate add at the IOL plane		-3.0 D to +3.0 D (0.5 D increments) -1.0 D to +1.0 D (0.25 D increments)  Trifocal, diffractive, +3.5 D near add and +1.75 D intermediate add at the IOL plane			

ı	Sulcoflex Trifocal IOL				
Material	Single piece Rayacryl hydrophilic acrylic	Single piece Rayacryl hydrophilic acrylic			
Water Content	26% in equilibrium	26% in equilibrium			
UV Protection	Benzophenone UV absorbing agent	Benzophenone UV absorbing agent			
UV Light Transmission	UV 10% cut-off is 380 nm	UV 10% cut-off is 380 nm			
Refractive Index	1.46	1.46			
ABBE	56	56			
Overall Diameter	12.5 mm	14 mm			
Optic Diameter	6 mm	6.5 mm			
Optic Shape	Biconvex (positive powers)	Anterior convex, posterior concave			
Asphericity	Aberration-neutral technology	Aberration-neutral technology			
Optic Edge Design	Amon-Apple 360° enhanced square edge				
Haptic Angulation	0°, uniplanar	10° Posterior			
Haptic Style	Anti-Vaulting Haptic (AVH) technology	Undulating and rounded C-loop haptics			
Estimated constant for power calc.		Expected lens position 4.5 mm			

	Sulcoflex Trifocal delivery system			
Injector Type	Single use, fully preloaded IOL injection system	Medicel ACCUJECT 1.8O-1 (LP604540)		
Incision Size	1.65 mm nozzle for 2.2 mm incision	1.8 mm nozzle for sub 2.2 mm incision		
Bevel Angle	45°	35°		
Lens Delivery	Single handed plunger	Single handed plunger		

Estimated Constants for Optical Biometry									
	SRK/T	Haigis		HofferQ	Holladay	Holladay II	Barrett Universal II		
	A-constant	a0	<b>a</b> 1	a2	pACD	SF	pACD	LF	DF
RayOne Trifocal & RayOne Trifocal Toric	118.6	1.044	0.40	0.10	5.32	1.56	5.32	1.67	3.5

For Contact Ultrasound, the estimated A-constant is 118.0  $\,$ 


Please note that the constants indicated for all Rayner lenses are estimates and are for guidance purposes only. Surgeons must always expect to personalise their own constants based on initial patient outcomes, with further personalisation as the number of eyes increases.

For Sulcoflex Trifocal lens calculations,

visit www.raytrace.rayner.com

#### References:

1.Eurotimes Supplement Feb 2019. RayOne Trifocal & Sulcoflex Trifocal. 2.Ferreira TB and Ribeiro FJ. J Refract Surg. 2019;35(7):418-425. 3.De Lange J. Ophthalmology Times Europe article March 2019. 4.Mathew RG and Coombes AGA. Ophthalmic Surg Lasers Imaging. 2010 Nov-Dec;41(6):651-5. 5.Bhogal-Bhamra GK et al. Journal of Refractive Surgery. 2019;35(1):48-53. 6.Nanovaty MA and Kubrak-Kisza M. J Cataract Refract Surg. 2017 Apr;43(4):558-563. 7.Prager Fet al. J Cataract Refract Surg. 2017;43(5):643-647. 8.Amon MI. Cataract Refract Surg Today Europe. 2009:56-9. 9.Kahraman G and Amon M. J Cataract Refract Surg. 2010 Jul;36(7):1090-4. 10.Manzouri B et al. Asia- Pacific Journal of Ophthalmology. Vol 6, Number 4, July/August 2017. 11.Khan MI, Muhtaseb M. CRSTE June 2010. 12.Claoué et al. CRST Euro Supple. 2009: 13.Amon MI et al. ESCRS Euro Times Supple. 2012:2-3. 14.Khoramnia R et al. J Refract Surg. 2020;36(9):570-577. 15. Imburgia A et al. Frontiers in Bioscience-Landmark. 2022; 27(2): 041.











©2023 Rayner Group, all rights reserved. Rayner, RayOne, Sulcoflex, AEON, RayPRO and Rayacryl are proprietary marks of Rayner. Medicel and ACCUJECT are proprietary marks of Medicel AG. Rayner, 10 Dominion Way, Worthing, West Sussex, BN14 8AQ. Registered in England: 615539. EC 2023-19 01/23